April 02, 2026 03:25 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead
Johnson & Johnson
Pixabay

Fight against COVID-19: Johnson & Johnson's vaccine shows strong immune response

| @indiablooms | Sep 26, 2020, at 02:21 pm

New Brunswick: US pharmaceutical major  Johnson & Johnson's potential COVID-19 vaccine has shown development of a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated.

The company published an interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) on Friday.

" Immune responses were similar across the age groups studied, including older adults," the company said in a statement.

"The ongoing Phase 1/2a clinical trial is designed to study the safety and immunogenicity of two dose levels of the Janssen COVID-19 vaccine, and as single and two-dose schedules," the company said.

The interim analysis showed that a single dose induced a robust immune response and was generally well-tolerated.  

" These data are consistent with preclinical studies, published in the scientific journal Nature, which showed that a single dose of the vaccine successfully prevented subsequent infection and provided complete protection in the lungs of nonhuman primates," read the statement.

"Based on these findings, the single dose of the Janssen COVID-19 vaccine candidate of 5x1010 virus particles (vp) has been selected for further evaluation in the Phase 3 ENSEMBLE clinical trial," the company said.

The company also plans on running a Phase 3 clinical trial of a two-dose regimen of JNJ-78436735 versus placebo later this year.

The full set of results will be published once the complete Phase 1/2a trial data are available.
" The Janssen COVID-19 vaccine candidate elicited strong antibody responses, strong T cell responses, and a Th1 response, believed to be protective against the risk of vaccine-associated enhanced respiratory disease," the company said.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.